Categories
Anticancer Drugs Oncology Palifermin Pharmacology Physiotherapy

Palifermin and Carcinogenicity

In this article we will discuss Palifermin and Carcinogenicity

In this article, we will discuss Palifermin and Carcinogenicity. So, let’s get started.

Palifermin and Carcinogenicity

No treatment-related increase in the incidence of neoplastic lesions occurred in transgenic rasH2 mice treated with 9 weekly intravenous doses of palifermin, at 167-fold higher than the recommended human dose (on a mcg/kg basis).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.